ROAD TO A CURE - National Psoriasis Foundation

2012 ANNUAL REPORT
ROAD TO A CURE
RESEARCH
INVESTMENTS
PAVE THE
WAY

Dear Supporter,
This has been a year of incredible breakthroughs in psoriasis and psoriatic arthritis research. The
National Psoriasis Foundation is proud to have played a leading role in supporting work toward
solving the puzzle of psoriasis.
Randy Beranek
President and CEO
In fiscal year 2012, the Foundation invested $2.21 million in our research program, including
grants and fellowships, our largest amount to date. We funded several studies that could improve
the lives of people with psoriasis and psoriatic arthritis. In the past year, the Foundation has:
»»
Funded a study by cardiologist Nehal N. Mehta, M.D., that shows inflammation in skin and
other organs and joints in people with psoriasis, suggesting a link between psoriasis to other
serious diseases.
»»
Backed research by Nicole Ward, Ph.D., that shows psoriasis can cause cardiovascular disease
and demonstrated that treating psoriasis can help reduce the risk of heart disease.
»»
Supported the work of Anne Bowcock, Ph.D., that identified the first gene directly linked to
plaque psoriasis.
Dan Farrington
Chair, Board of Trustees
EDITORIAL STAFF
Catie Coman
Vice President of Marketing
and Communications
Tamara Miller
Editor/Writer
Tina Rouhoff
Creative Services Manager
Julianna Johnson
Graphic Designer
All told, the Foundation awarded 26 grants and fellowships in 2012 to researchers whose projects
have the potential to improve treatments for people with psoriasis and psoriatic arthritis and,
ultimately, lead to a cure. Our investment is intended to help promising researchers get their
studies off the ground and eventually attract long-term funding. We have had success in reaching
that goal. Both Drs. Mehta and Ward used the results from their Foundation-backed studies
to apply for and receive funding from the National Institutes of Health, the largest source of
medical research funding in the world.
In this report, you’ll learn more about promising studies backed by the Foundation that have the
potential to make psoriasis treatments more affordable and accessible and help doctors diagnose
psoriatic arthritis earlier.
Your generous contributions were essential to the progress made over the past year. Thanks to
your support, the Foundation exceeded $8 million in total revenue, including a record
$2.03 million in net revenue in 2012 through special events, such as the inaugural Commit to
Cure Gala and the Walk to Cure Psoriasis. With your help, we can achieve our mission to find a
cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects.
Sincerely,
Randy Beranek
President and CEO
Dan Farrington
Chair, Board of Trustees
2012 ANNUAL REPORT • 1

The mission of the National Psoriasis Foundation is
to find a cure for psoriasis and psoriatic arthritis
and to eliminate their devastating effects through
research, advocacy and education.
THE FOUNDATION HAS A
FIVE-POINT ACTION PLAN
TO FIND BETTER TREATMENTS AND A CURE:
1
Fund the startup of
promising new and
innovative studies
through our Discovery
and Translational
Grants
2
Increase the number
of scientists doing
psoriatic disease
research through
our Medical Research
Fellowship program
3
Provide scientists with
DNA samples through
the National Psoriasis
Victor Henschel
BioBank, aiding their
search for specific
genes that cause
psoriasis and psoriatic
arthritis
4
Work with federal
policymakers to
increase government
investment in psoriatic
disease research
5
Promote patient
involvement in
research studies and
clinical trials, vital
to bringing safe and
effective treatments
to market
1966
1968
MILESTONES
Classified ad placed in a
Portland, Ore. newspaper
to connect people
affected by psoriasis
National Psoriasis
Foundation founded in
Portland, Ore.
1970
NPF sponsors the first
National Institutes
of Health psoriasis
workshop for 105
scientists
2 • NATIONAL PSORIASIS FOUNDATION

2012
FOUNDATION
HIGHLIGHTS
FY2012 BY THE NUMBERS
7.5 MILLION
Number of people with
psoriasis
30 PERCENT
Estimated percentage of
people with psoriasis who
have psoriatic arthritis
$2.21
MILLION
Amount the Psoriasis
Foundation invested
in research, highest
amount to date
2.1 MILLION
visits to psoriasis.org
& TalkPsoriasis.org
200,000
Number of e-newsletter
subscribers
15,506
Facebook fans, a
41-percent increase
from 2011
4,796
Twitter followers, an
85-percent increase
from 2011
5,822
Number of people who
joined TalkPsoriasis in
the last year
10,200
Number of TalkPsoriasis
users, an almost
57-percent increase
from 2011
1,076
Number of More than
Skin Deep participants
3,857
Number of Psoriasis
Foundation webinar
viewers
225,000
Number of people with
psoriatic disease who
receive better insurance
coverage and access to
care as a direct result
of Psoriasis Foundation
advocacy efforts
2,622
Number of times
Foundation staff
responded to health,
insurance, discrimination
and other
information requests
165,000
Estimated number of
readers of the Psoriasis
Advance
MORE THAN
2.1 MILLION
Number of people served
by the National Psoriasis
Foundation
5,320
Number of times the
National Psoriasis
Foundation was
referenced or contacted
for news stories,
including in the
Huffington Post, Wall
Street Journal, Women’s
Health magazine, PBS
and the New York Times
5,000
Number of letters sent
to the U.S. Congress by
Foundation advocates
$2,035,017
Net amount raised
through Walk to Cure
Psoriasis and other
special events
$8,985,621
Donations, special
events, and other
revenue, largest amount
in Foundation history
26
Number of grants and
fellowships awarded by
the Psoriasis Foundation
1974
NPF helps create the
first NIH grant for
psoriasis research,
which was awarded
to the University of
Michigan
1974
NPF successfully
lobbies for FDA
approval of
methotrexate
1975
National Psoriasis
Foundation launches
its research grant
program
1975
NPF secures the first
federally-mandated
funding for psoriasis
research
2012 ANNUAL REPORT • 3

The Road to a Cure
Begins with Basic Research
1975
NPF awards its first
research fellowships
to young scientists
studying psoriatic
diseases
1976
NPF successfully
lobbies the FDA to
prevent removal of
over-the-counter coal
tar from market
1981
NPF successfully
lobbies the FDA for
PUVA approval
1987
NPF awards its first
annual psoriasis
research grants
4 • NATIONAL PSORIASIS FOUNDATION

1994
National Psoriasis
Foundation Tissue
Bank is established to
study the genetic basis
of psoriasis
1994
NPF awards its first
research grant for
psoriatic arthritis
1998
First biologic
medications to
treat psoriasis are
introduced
1999
NPF holds its first
annual Residents
Meeting to train young
physicians how to treat
psoriatic diseases
2012 ANNUAL REPORT • 5

2002
Etanercept (Enbrel)
is the first biologic
approved by the FDA
to treat psoriatic
arthritis
2003
Three genes linked to
psoriasis are found
by NPF-supported
researchers using data
from the NPF Tissue
Bank
2005
National Psoriasis
Foundation launches
its advocacy
department
Imagine if you could find out you were becoming
seriously ill —before having any symptoms. Now
imagine if you could take medicine and lessen the
severity of the symptoms to come—or eliminate
them entirely.
That’s the idea behind the research of University
of Pennsylvania rheumatologist and researcher
Dr. Alexis Ogdie.
DISCOVERY GRANT
RESEARCHER
DR. ALEXIS
OGDIE
The National Psoriasis Foundation awarded Ogdie
the one-year, $50,000 A. Marilyn Sime Discovery
Grant to continue her study into whether wholebody
scans made with imaging technology can be
used to detect psoriatic arthritis before it causes pain
and swelling of the joints. The research gives hope to
the idea that psoriatic arthritis can be detected, and
treated, earlier and before significant joint damage.
SIGNS BEFORE SYMPTOMS
Of the 7.5 million people living with psoriasis, an
estimated 30 percent of them have psoriatic arthritis.
A good portion of people with psoriatic arthritis do
not have significant flares on the skin.
That’s just one of the reasons psoriatic arthritis can
be difficult to diagnose.
Illustration © veer.com/artist/bubaone
“Psoriatic arthritis has such a varied presentation,”
Ogdie said. “Every patient looks different.”
6 • NATIONAL PSORIASIS FOUNDATION

2005
National Psoriasis
Foundation holds its
first annual Capitol
Hill Day, bringing
advocates to speak
with Congress about
psoriatic diseases
2006
National Psoriasis
Victor Henschel
BioBank is founded
to study the roles of
genes in psoriatic
diseases
2007
Psoriasis is linked to
increased risk of heart
disease
2007
Psoriasis and Psoriatic
Arthritis Research,
Cure, and Care Act
(PPARCCA)—the first
psoriasis and psoriatic
arthritis legislation—is
first introduced into
Congress
Unlike rheumatoid arthritis, there currently is no
blood test to determine if a person has psoriatic
arthritis. Doctors use a combination of ways to
diagnose psoriatic arthritis: patient history, physical
exam, X-rays, magnetic resonance imaging (MRI)
and ultrasound.
Ogdie’s team will use Positron Emission
Tomography/Computed Tomography, or PET/CT
scans to look for a form of sugar, glucose, in the body,
using the idea that inflammatory cells take up sugar
to create inflammation.
Already, Ogdie’s team has found inflammation in
the joints of psoriasis patients who have not yet
experienced symptoms of psoriatic arthritis. That has
the potential to improve patient outcomes.
“If you could diagnose the disease earlier, you can
prevent the bad inflammation and joint deformities
that occur in the disease,” Ogdie said.
RESEARCH BREAKTHROUGHS
Ogdie’s research builds on that of another
Foundation-backed researcher and fellow
University of Pennsylvania researcher, cardiologist
Dr. Nehal N. Mehta. Mehta was the lead author of a
study, also funded by a Discovery Grant, that created
images showing inflammation in several organs of
people with psoriasis. Studies showing the connection
between psoriatic diseases and comorbidities, such as
Type 2 diabetes, stroke and heart disease, have given
momentum to psoriasis research.
“It’s great that there is growing interest in psoriasis,”
Ogdie said. “Knowing more about subclinical
diseases, such as inflammation with patients with
psoriasis … helps us in identifying which treatments
are working and how.”
The Foundation’s Discovery Grant was critical to
Ogdie’s research, she said.
“This was absolutely necessary, because there was no
other funding available at the time,” Ogdie said.
A. MARILYN SIME DISCOVERY GRANT
A. Marilyn Sime, Ph.D., R.N., has
lived with psoriasis and psoriatic
arthritis since her 20s. She also is a
professor emerita at the University
of Minnesota School of Nursing and
spends much of her time teaching
graduate students research
methodology.
She recently combined her interests
to provide $50,000 for the oneyear
National Psoriasis Foundation
Discovery Grant awarded to Dr. Alexis
Ogdie, University of Pennsylvania
rheumatologist and researcher.
Sime has been a generous donor for
more than 20 years.
Illustration by Julianna Johnson
“As someone living with psoriasis and
psoriatic arthritis, Sime has a unique
perspective,” said Board Chairman
Dan Farrington. “We are honored
that she has chosen to invest in the
Foundation’s work to find better
treatments, and ultimately, a cure.”
2012 ANNUAL REPORT • 7

2008
Scientists at
Washington University
School of Medicine in
St. Louis uncover 7
new DNA variations, or
genetic links, involved
in psoriasis
2008
Aetna improves
its insurance plan
for people with
psoriasis based on
recommendations
from the National
Psoriasis Foundation
MARCH
2009
Grammy Awardwinning
artist LeAnn
Rimes travels with the
NPF to Capitol Hill to
share her psoriasis
story with Congress
JULY
2009
LeAnn Rimes asks
Congress to grant
$1.5 million to the
CDC for a psoriasis
patient registry
Lotions and pills often aren’t enough to keep the
symptoms of moderate to severe psoriasis and psoriatic
arthritis at bay.
TRANSLATIONAL
GRANT
RESEARCHER
DR. SAM
HWANG
For many people with psoriatic diseases, the most
effective treatment comes from taking biologics—
a medicine derived from living cells cultured in a
laboratory. Right now, the only way to receive biologic
medicine is through infusions or needle syringes and let
it circulate throughout the body. That spells relief for
many, but not always: Biologics are expensive, require
regular doctor’s office visits and don’t work for everyone.
However, promising research led by Dr. Sam Hwang
of the Medical College of Wisconsin could lead to
more affordable and more accessible treatment in the
future.
Illustration © veer.com/artist/bubaone
Funded by the two-year, $200,000 National Psoriasis
Foundation Lutto Translational Grant, Hwang and
his team of researchers hope to find small-molecule
compounds that will block a protein produced by the
body called CCR6, which has been linked to psoriasis
inflammation. If successful, those small-molecule
compounds – smaller than those used in biologics
today – could be formulated into a less-expensive and
easy-to-take cream, ointment or pill.
8 • NATIONAL PSORIASIS FOUNDATION

DECEMBER
2009
Congress approves
$1.5 million for the
first-ever psoriasis
data collection at
the CDC
SEPTEMBER 1
2010
First DNA samples
from the National
Psoriasis Victor
Henschel BioBank
released for study
OCTOBER
2010
New York becomes
the first state to ban
specialty tiering of
prescription drug
prices by insurance
companies
APRIL
2011
Psoriasis is associated
with double the
risk for metabolic
syndrome—a cluster
of conditions such as
heart disease, high
blood pressure and
abdominal obesity
THE SCIENCE OF PSORIASIS
Hwang’s research team has been studying a family
of proteins called chemokine receptors, which move
human cells from one place to another. The team
discovered that mice lacking the chemokine receptor
CCR6 do not develop the skin inflammation in
psoriasis. The team also discovered that blocking
another chemokine, CCL20, prevented the
development of psoriasis.
Hwang’s team is using the Translational Grant to
search for molecules that can block CCR6 and CCL20.
By using sophisticated computer systems, they
hope to find small molecules that a pharmaceutical
company can formulate into a cream, ointment or pill
that would prevent mild to moderate psoriasis flares.
So far, the team is off to a good start.
“Within three months of starting, we’ve already
identified one compound,” Hwang said. “I would
fully expect to identify three to five lead compounds
in the next one or two years.”
FROM THE LAB
TO THE BEDSIDE
Hwang has long had an interest in the role chemokine
receptors play in autoimmune diseases.
“Being in dermatology and seeing psoriasis patients
all the time, it really struck me that this kind of data
could lead to better therapy for psoriasis,” Hwang
said.
His team’s research could be used to help treat other
autoimmune diseases, such as rheumatoid arthritis.
The Foundation’s support has been critical to
furthering Hwang’s research. It’s also helped him
realize the needs of people with psoriasis and psoriatic
arthritis. In his opinion, the future of psoriatic disease
research looks very bright.
“There’s going to be a lot (of research) in the next five
to six years that will make treatment more effective,
cheaper and easier on the patient,” Hwang said.
WHAT IS A BIOLOGIC?
Biologics are made from antibodies—
very large proteins created by the
human body to fight infection. Those
antibodies help people with diseases
like psoriasis and psoriatic arthritis
by blocking certain cells or chemical
messengers in the immune system.
Most biologics used today block a
chemical messenger called tumor
necrosis factor-alpha, or TNF-alpha.
There is too much TNF-alpha in
the skin and joints of people with
psoriasis and psoriatic arthritis.
This leads to the rapid growth of
skin cells typical of psoriasis, or to
the joint inflammation characterized
by stiffness, pain, warmth and
redness seen in psoriatic arthritis.
A reduction in TNF-alpha, a critical
regulator of inflammation, stops the
inflammatory cycle of psoriasis and
psoriatic arthritis.
Because antibodies are so large,
they have to be injected or infused
into the body—the medicine literally
is too large to put in a pill or lotion.
A typical biologic costs a minimum
of about $2,000 per month, before
insurance.
ABOUT THE LUTTO BEQUEST
$2 MILLION—largest in
Foundation history
Larry Lutto struggled with psoriasis
for much of his life. After he died at
age 32, his parents wanted to help
find better treatments and a cure so
that others would not suffer as their
son had. Seymour (Sy) and Rebecca
Lutto named the National Psoriasis
Foundation as a beneficiary in their
living trust agreements. Both died
within months of each other in 2011.
“In honor of their very generous
contribution, the Foundation
established the Lutto Translational
Grant to fund research focused
on rapidly translating scientific
discoveries that will clearly benefit
people with psoriasis and psoriatic
arthritis,” said Board Chairman
Dan Farrington.
Sy Lutto was a copy editor for
The New York Times for 47 years. He
is remembered for his humor, kind
heart and modesty. Rebecca Lutto
worked as a librarian and freelance
writer, and earned some attention for
a letter to the editor to The New York
Times that included the oft-quoted
statement, “Sometimes inefficiency
is the price we pay for democracy.”
On behalf of all families who struggle
with psoriasis and psoriatic arthritis,
we will honor their legacy by
continuing to invest in research that
will one day pay off with a cure.
2012 ANNUAL REPORT • 9

MAY
2011
Obesity in childhood
found to significantly
increase risk for
psoriasis
AUGUST
2011
Capital Blue Cross
improves its insurance
plan for people with
psoriasis based on
recommendations
from the National
Psoriasis Foundation
OCTOBER 12
2011
NPF research reveals
nearly one in four
people with psoriasis
may have undiagnosed
psoriatic arthritis
FEBRUARY
2012
Premera Blue Cross
improves its insurance
plan for people with
psoriasis based on
recommendations
from the National
Psoriasis Foundation
VOLUNTEER BOARD
OF TRUSTEES
Daniel Farrington
Chair
Bethesda, Md.
Krista Kellogg
Chair-Elect
Miami, Fla.
Mark S. Lillie
Vice-Chair
Chicago, Ill.
Eric Kimble
Secretary
Sudbury, Mass.
Chip Newton
Treasurer
St. Petersburg, Fla.
Steve Bishkoff
Oakhurst, N.J.
Colby Evans, M.D.
Austin, Texas
Holly Fields Krafsur
El Paso, Texas
Kathleen L. Gallant
Pittsburgh, Pa.
Lawrence Green, M.D.
Rockville, Md.
Sarah Kurts, PA-C
Denver, Colo.
Michael Laub
New York, N.Y.
Mark G. Lebwohl, M.D.
New York, N.Y.
Pete Redding
Reno, Nev. and
Phoenix, Ariz.
Terri Theisen
Atlanta, Ga.
ex officio
Richard Seiden
Immediate Past Chair
Los Angeles, Calif.
VOLUNTEER MEDICAL BOARD
Mark G. Lebwohl, M.D.
Chair
New York, N.Y.
Lakeshi M. Aldredge, M.S.N.,
R.N., A.N.P.-B.C.
Portland, Ore.
Jerry Bagel, M.D.
East Windsor, N.J.
Andrew Blauvelt, M.D.
Portland, Ore.
Erin Boh, M.D., Ph.D.
Covington, La.
Kristina Callis Duffin, M.D.
Salt Lake City, Utah
Jeffrey Crowley, M.D.
Los Angeles, Calif.
Lawrence Eichenfield, M.D.
San Diego, Calif.
Alice Gottlieb, M.D., Ph.D.
Boston, Mass.
Sylvia Hsu, M.D.
Houston, Texas
Elaine Husni, M.D., M.P.H.
Cleveland, Ohio
Abby A. Jacobson, M.S.,
P.A.-C
Lancaster, Pa.
Arthur Kavanaugh, M.D.
La Jolla, Calif.
Gerald G. Krueger, M.D.
Chairman Emeritus
Salt Lake City, Utah
Abrar Qureshi, M.D.,
M.P.H.
Boston, Mass.
Christopher Ritchlin, M.D.
Rochester, N.Y.
Linda Stein Gold, M.D.
West Bloomfield, Mich.
Stephen Stone, M.D.
Springfield, Ill.
Abby Van Vorhees, M.D.
Philadelphia, Pa.
Jeffrey Weinberg, M.D.
New York, N.Y.
Gerald D. Weinstein, M.D.
Chairman Emeritus
Irvine, Calif.
Stefan Weiss, M.D.
Boca Raton, Fla.
Paul Yamauchi, M.D., Ph.D.
Encino, Calif.
TREASURER’S LETTER
On behalf of the National
Psoriasis Foundation Board
of Trustees, I want to extend
my deep gratitude to you, our
donors. For the 2012 fiscal
year, we received revenue of
$8.9 million in gifts, pledges
and other support, an increase of 25 percent over
the prior year. Your support helps to advance our
mission to find a cure for psoriasis and psoriatic
arthritis and to eliminate their devastating effects
through research, advocacy and education.
We are continuing our focus on finding a cure for
psoriasis and psoriatic arthritis and to increase
our spending on research activities. During the
fiscal year we awarded 15 new research grants
totaling $1,397,320 and continued our Medical
Dermatology Fellowship Program by funding
twelve fellowship grants totaling $464,500. We
continue to build the BioBank to further the study
of psoriasis genetics. We also held our first Commit
to Cure Gala which grossed $1 million to further
research awards.
In its sixth year, our National Psoriasis Walk to
Cure program raised $1,336,000. We are thankful
to the many individuals and corporate sponsors
who are helping to make this program increasingly
successful.
During this fiscal year we committed over
$6.1 million, or 80 cents of every dollar spent,
to programs which advance the mission of the
Foundation. Our balance sheet remains strong with
$7.4 million in assets. We are committed to being
fiscally responsible so that we can continue our
mission during tough economic times.
Thank you for your generosity.
Sincerely,
Chip Newton
10 • NATIONAL PSORIASIS FOUNDATION

MARCH
2012
Study finds that
treating psoriasis with
anti-TNF agents may
reduce heart attack
risk
APRIL
2012
NPF-funded researcher
receives a $7 million
award from the NIH
to study connection
between psoriasis and
heart disease
APRIL
2012
Scientists use DNA
from the National
Psoriasis Victor
Henschel BioBank
to identify the first
gene linked to plaque
psoriasis
YEAR ENDED JUNE 30, 2012
STATEMENT
OF ACTIVITIES
STATEMENT OF
FINANCIAL POSITION
REVENUE, GAINS AND
OTHER SUPPORT
$2,035,017
Net special events revenue
EXPENSES
$2,208,929
Research
ASSETS
$6,128,440
Investments, cash
& cash equivalents
LIABILITIES
$348,291
Accounts payable and
accrued liabilities
$1,320,813
Individual contributions
$2,587,162
Corporate contributions,
Foundation contributions
and sponsorships
$2,102,585
Legacies and bequests
$940,044
Fees, advertising and other
TOTAL REVENUE, GAINS
AND OTHER SUPPORT
$8,985,621
INCREASE IN NET ASSETS
$1,309,785
$842,543
Advocacy and
government relations
$784,166
Patient services
$1,790,540
Public education
$535,392
Professional education
$1,109,673
Fundraising
$404,593
Management and general
TOTAL EXPENSES
$7,675,836
$548,214
Pledges receivable-net
$420,400
Legacies and bequests
receivable
$183,620
Other assets
$172,777
Accounts receivable
TOTAL ASSETS
$7,453,451
$19,370
Deferred revenue
TOTAL LIABILITIES
$367,661
NET ASSETS
$5,223,157
Unrestricted
$1,862,633
Temporarily
restricted
TOTAL NET ASSETS
$7,085,790
TOTAL LIABILITIES
& NET ASSETS
$7,453,451
29%
Research 23%
Public education
12%
Advocacy and
government
relations
5%
Management
and general
17%
Professional
education and
patient services
14%
Fund raising
A complete copy of our
audited financial statments
is available on our website
at www.psoriasis.org.
2012 ANNUAL REPORT • 11

JULY 1, 2011–JUNE 30, 2012
CORPORATE PARTNERS
AND SPONSORS
Thank you to the corporations and
organizations that donated their time,
funds and support to the National Psoriasis
Foundation. Through their contributions,
we are able to advance our mission to find a
cure for psoriasis and psoriatic arthritis, as
well as provide information and support to
those coping with the disease.
PROGRAMS FUNDED BY OUR CORPORATE
PARTNERS AND SPONSORS INCLUDE:
Be Joint Smart: In its second year, this coalition
of the Arthritis Foundation and National Psoriasis
Foundation continued to raise awareness about
psoriatic arthritis and expanded to provide free
education seminars for people with psoriatic arthritis
on disease management, treatment and research.
This program is made possible by funding from
Amgen Pfizer.
Medical Education: Caring for psoriasis requires
familiarity with many different treatment regimens,
knowledge of the latest research and a deep
understanding that the chronic nature of psoriasis
necessitates consistent and long-term care. The
National Psoriasis Foundation continued hosting
its two annual medical education programs, the
Residents Meeting and Physician Assistants
Psoriasis Summit, to link psoriasis and psoriatic
arthritis experts with dermatologists and allied
health professionals. Residents Meeting was made
possible by funding from Abbott Laboratories,
Amgen Pfizer, Beiersdorf, Inc., Daavlin and
Galderma. Physician Assistants Psoriasis Summit
was made possible by funding from Abbott
Laboratories, Amgen Pfizer, Daavlin, Galderma
and Janssen BioTech, Inc.
Medical Research Fellowships: Today, there is a
shortage of researchers with in-depth expertise on
psoriasis and psoriatic arthritis. The National Psoriasis
Foundation Medical Research Fellowship program
seeks to increase the number of scientists focused on
studying and treating psoriasis and psoriatic arthritis
by encouraging young scientists to become physician
researchers and dedicate their careers to psoriatic
diseases. The National Psoriasis Foundation
Research Fellowships are made possible by a
grant from Amgen.
More Than Skin Deep: More than 1,000 people
with psoriasis and psoriatic arthritis, their family
members and caregivers attended 22 free education
seminars held by the National Psoriasis Foundation
across the U.S. Participants had the opportunity
to learn more about how to control their disease
from some of the best health care providers in the
country. More Than Skin Deep features a leading
dermatologist and rheumatologist to discuss
symptoms, diagnosis, treatment and management
options, as well as the latest research advances toward
a cure. These seminars were made possible by
funding from Abbott Laboratories, Amgen Pfizer,
Beiersdorf, Inc., Janssen BioTech, Inc., Galderma,
Neutrogena and Novartis Pharmaceuticals.
MAY
2012
NPF-supported
study identifies how
psoriasis and heart
disease are connected,
shows treating
psoriasis reduces
cardiovascular risk
MAY 15
2012
National Psoriasis
Foundation awards
more than $2.21
million in grants and
fellowships to 26
scientists studying
psoriatic diseases
JUNE
2012
Psoriasis linked to
independent risk for
type 2 diabetes
JULY
2012
Massachusetts passes
legislation enabling
access to patient
assistance programs
12 • NATIONAL PSORIASIS FOUNDATION

$1 MILLION +
$500,000-$999,999
SUPPORT FROM
INDIVIDUALS,
FOUNDATIONS AND
COMPANIES
JULY 1, 2011–JUNE 30, 2012
BEVERLY FOSTER HALPRIN SOCIETY
Named to honor the founder of the National Psoriasis Foundation
$250,000-$499,999
$75,000 OR MORE
Michael and Carol Laub
$50,000 TO $74,999
Michael Graff and Carol Ostrow
A. Marilyn Sime, Ph.D., R.N.
$100,000-$249,999
$25,000-$49,999
Valeant Pharmaceuticals
RICHARD COFFMAN CIRCLE
Named to honor the first chairman of the Psoriasis Foundation Board of Trustees
$25,000 TO $49,999
Jodi and Bill Felton
Neal and Barbara Henschel and Family
Mark G. Lebwohl, M.D.
Edward Lewis and Achara Pinpanna
Chip Newton and Liz Smith
$10,000-$24,999
Beiersdorf, Inc.
Celgene Corporation
Daavlin
Fougera Pharmaceuticals
Neutrogena
Novartis Pharmaceuticals
Pfizer, Inc.
PharmaDerm
PhotoMedex
Ranbaxy Pharmaceuticals
CHAMPIONS
$10,000 TO $24,999
Anonymous (2)
Susan Bershad, M.D.
Robert and Lauren Fales
Daniel and Rebecca Farrington
Steven Feldman, M.D., Ph.D.
and Leora Henkin
Millie Fleskes
C. M. Garver
Donald and Lesley Grilli
Judy and Stanley Katz
The Katz Family Foundation
Virginia Morris Kincaid
Charitable Trust
Jacob Levitt, M.D.
Mark and Celine Lillie
The Edward A. &
Catherine L. Lozick
Foundation
Tom and Laurie Markham
National Society for Cutaneous
Medicine
Owens & Minor
Chester and Jacqueline Paulson
Florence Petrlik
Randi Rahm
Steven Rand and Nancy Wender
Peter and Lorelei Redding
Victoria W. Sack
Richard and Ellen Seiden
Alan and Bari Shaffran
Sun Capital Partners
Foundation
Terri Theisen
University of Pennsylvania
The Webb Foundation
Michael and Melissa Weinbaum
& The Attilio & Beverly
Petrocelli Foundation
Dale and Karen White
Seth and Deb Wohlberg
Carol A. Yermal
2012 ANNUAL REPORT • 13

RECOGNITION OF GIFTS
MADE JULY 1, 2011
THROUGH JUNE 30, 2012
BENEFACTORS
$5,000 TO $9,999
Altman Dermatology
Associates
Aventura Mall Marketing Fund
Jerry Bagel, M.D.
Fabio Cuiabano Barbosa, M.D.
Randy Beranek
Frederic Bloch
Erin E. Boh, M.D., Ph.D.
Stan Burnstein
Sanford P. & Irene Burnstein
Foundation
Corey Cardine
Russell, Judith, Cecily and
Edward Carson
Case Western Reserve
University
Jennifer Clay Cather, M.D.
Joseph and Elizabeth Chan
James Q. Del Rosso, D.O.
Dermatology Nurses
Association
Drinker Biddle & Reath
Fisher Brothers Foundation
Dick and Meryl Friedman
Honor N. Fullerton, M.D. and
David Stone
Irwin and Joan Geduld
Jeff and Lisa Henschel
Infinite Healthcare Partners
Irish Network San Francisco
MULTI-YEAR PLEDGES
These donors have made long-term commitments to
provide essential support for Foundation programs.
$1 MILLION
Neal and Barbara Henschel
and family for the National
Psoriasis Victor Henschel
BioBank
$250,000 TO
$499,999
Edward Lewis and Achara
Pinpanna
$50,000 TO
$99,999
Bill and Jodi Felton
Dale and Karen White
14 • NATIONAL PSORIASIS FOUNDATION
Benjamin and Janice Isenberg
Jewish Community Foundation
Michael J. John
Krista Kellogg
Eric W. Kimble
Leon Kircik, M.D.
Kirkland & Ellis Foundation
John Y. M. Koo, M.D.
Krafsur Family
Gerald G. Krueger, M.D.
Levitt Research Foundation
Medicis, The Dermatology
Company
Alan Menter, M.D. and
Pam Menter
Microsoft Corporation
Mark Oberman and
Judith Eisenberg
Organization of Teratology
Information Specialists
David Michael Pariser, M.D.
Phoebe Rich, M.D.
Marc & Carolyn Rowan Family
Foundation
James A. Schamus
Lutz Schlicht
Schwab Charitable Fund
Society of Dermatology
Physician Assistants
Stanford Dermatology
Linda Stein Gold, M.D.
Jack and Alice Styza
Taro Pharmaceuticals
Bruce Thiers, M.D.
Christina W. Tom
University of Michigan
Eugene J. Van Scott, M.D.
$25,000 TO
$49,999
Randy Beranek
Daniel and Rebecca
Farrington
$10,000 TO
$24,999
Bill Cardamon and
Alicia Wright
Benjamin and Janice Isenberg
Krista Kellogg
Eric W. Kimble
Abby S. Van Voorhees, M.D.
Walton Family Foundation
Byron Webb
Fred and Joan Weisman
Stefan Weiss, M.D.
Mark and Blanche Wine
Paul S. Yamauchi, M.D., Ph.D.
GUARANTORS
$1,000 TO $4,999
Acorn Hill Foundation
Adobe Systems Incorporated
Advanced Care Scripts
Advanced Dermatology and
Skin Cancer Center
Kent Aftergut, M.D.
Douglas Altchek, M.D.
American Century Investments
Nancy J. Anderson, M.D.
Dr. David W. Andrews
Anonymous (8)
Humberto C. Antunes
Ashish Anvekar
Rob Arango and The Plaza
Marc Arginteanu, M.D. and
Ronit Arginteanu
Arlington Center for
Dermatology
Anthony M. Armada, M.D.
Veronica Arnstein
Ashland Foundation
Louis and Susan Axelrod
Bank of America Charitable
Gift Fund
Baptist Health South Florida
Tom and Ellen Barton
Joe and Nelda Beaud
Vincent Peter Beltrani, Jr.,
M.D.
Sonia Bender
Paula and Jordan Bergstein
Brian Berman, M.D., Ph.D.
J. Raymond Bernat, M.D.
Michael Bernhardt, M.D.
Neal Bhatia, M.D.
Jeffrey Biegelsen
The Biegelsen Foundation
Joseph B. Bikowski, M.D.
Steven and Tracy Bishkoff
Bonne, Bridges, Mueller,
O'Keefe & Nichols
Richard K. Bowman
BPM Northwest
David H. Brockway
Eileen Brooks
R. Steven Brooks
Suzanne Bruce, M.D.
Jean R. Bruder
Mary Ruth Buchness, M.D.
Build-A-Bear-Workshop Hugs
Foundation
Marian C. Burke
Jeffrey P. Callen, M.D.
Kristina Callis Duffin, M.D.
Bill Cardamon and Alicia
Wright
Caremark RX
Patrick Carney, M.D.
Cary Dermatology Center
Michael and Carey Cavaliere
Roger I. Ceilley, M.D.
Brad and Judy Chase
Yoo Sang Choi
Michael Cisewski
Mary R. Clarbour
Cleveland Clinic Foundation
CNA Insurance Companies
Clay Cockerell, M.D. &
Coquerel Family
Wine Estates
Russell W. Cohen, M.D.
Steven R. Cohen, M.D., M.P.H.
Myron and Nancy Cohn
Colorado Dermatologic Society
Colorado Society of
Dermatology Professionals
Colorado Springs Dermatology
Clinic
Catie Coman and
Scot Robinson
Meredith Conte
The James Cook Family
Kimberly and Robert Coretz
CPS 5
Jeffrey Crowley, M.D. and
Sarah Crowley
Daavlin
Theodore Daly, M.D.
Thomas B. Daniels
Ronn and Nicole Davids
Robert Day, Ph.D. and
Flora Day
Vincent A. Deleo, M.D.
Dermatology & Aesthetics of
Wicker Park
Dermatology and Laser
Institute of Colorado
Dermatology Associates of
Morris
Diplomat Specialty Pharmacy
Paul and Ivy Dodwell
Amit Doshi
Terrance A. Doyle
Joseph S. Eastern, M.D.
Elorac
Colby C. Evans, M.D.
The Roy Gene & Pamela Evans
Foundation
Evince Communications
Fahringer Foundation
Carrie and Steven Falkner
Patrick R. Feehan, M.D.
Edward Feigeles
Neil A. Fenske, M.D.
Adolfo Fernandez-Obregon,
M.D.
Mathew Edward Saul Firman
Mark and Tara Flint
Ted Floor
Foley & Lardner
Form Analysis
Ellen H. Frankel, M.D.
Mark H. Fritze
GEICO Philanthropic
Foundation
Leonard Genet
Robert and Adrienne
Ginsberg
Dafna Gladman, M.D.
Brad P. Glick, D.O.
Gold & Rosenblatt
Henry L. Goldberg
The Goldfein Family
Foundation
Gail Goldman, M.D.
Norman Goldstein, M.D.
Arlene & Arnold Goldstein
Family Foundation
Amy Goleno
Michael D. Good
Good Works Health Inc.
Google Gift Matching Program
Alice Bendix Gottlieb, M.D.,
Ph.D.
Richard D. Granstein, M.D.
Lawrence Green, M.D. and
Allison Green
Robert G. Greenberg, M.D.
Stephanie E. Grobaski
Kenneth A. Grossman, M.D.
Wolfgang Guenther, M.D. and
Lyn Guenther
Paula H. Gwosdz
H&R Block
Charles L. G. Halasz, M.D.
Barry Hartzberg
David and Wendy Hashmall
Steven N. Hecht
Andrew and Nancy Henschel
Warren R. Heymann, M.D.
Margaret Hiler
Robert J. Hiler Family
Foundation
Holy Family School
Francis W. Iacobellis, M.D.
Innocutis Holdings
Ernest Isenstadt
Ronen Israel
Brett Janecek
Peter J. Jenkin, M.D.
Brian Johnson
Dorothy Judevine

The National Psoriasis Foundation hosted its
inaugural Commit to Cure Gala on June 7, 2012,
which honored Dr. Mark Lebwohl, chairman of the
Psoriasis Foundation Medical Board and a longtime
leader in the organization.
More than 400 people gathered in the Grand
Ballroom of New York’s Plaza Hotel. The event
raised $1 million for the Dr. Mark G. Lebwohl
Medical Dermatology Fellowship Awards
to encourage early-career dermatologists
to pursue psoriasis and psoriatic arthritis
research. Students who have completed a
three-year dermatology residency program
or at least one year of a four-year program
that includes a research year will be eligible for
fellowship grant. Applicants must devote at least
75 percent of their effort to psoriatic disease
research and their mentors must have an academic
appointment in a dermatology program.
Dr. Lebwohl is highly respected around the
world for his contributions to psoriasis
research and patient care. He has served as
the Psoriasis Foundation’s Medical Board chair
for more than a decade and has encouraged
young researchers to pursue psoriasis research
throughout his career. Dr. Lebwohl is noted for his
advocacy for patients and his contributions to the
Foundation.
Photo by D&L Photography,
Linda Pedersen/David Kenny
Thank you to the top Commit to Cure Gala Corporate Sponsors: Abbott Laboratories,
Amgen Pfizer, Beiersdorf, Inc., Celgene Corporation, Fougera Pharmaceuticals,
Galderma, Janssen BioTech, Inc., Leo Pharma, Inc., Lilly USA, LLC, Medicis
Pharmaceuticals, PharmaDerm, PhotoMedex, Ranbaxy Pharmaceuticals,
Taro Pharmaceuticals and Valeant Pharmaceuticals.
a
Robert E. Kalb, M.D.
"Lab Rat"
Kansas City Dermatology
Michael and Jacqueline Katz
Susan E. Katz, M.D.
The Katz Family Foundation
Craig Kauffman
Jacquelyn C. Keaveney
Alexandra B. Kimball, M.D.,
M.P.H.
Virginia Morris Kincaid
Charitable Trust
William and Frances Klein
Scott and Patricia Klevenhagen
Kohl's
Neil Korman, M.D., Ph.D.
Michael Kraley
Indira Rao Krishnarao, M.D.
Wesley Kroger
Caren Krumerman
Kristine Kucera, PA-C, MPAS,
DHS
Sarah A. Kurts, PA-C
Priscilla and Richard Kurz
Kathleen M. LaCroix
Michael and Jill Lamoretti
SaraLee and Barry Larner
Craig and Sharon Larson
Andrew and Lori Laub
Robyn and Marc Leach
Lerner Medical Devices
Ross S. Levy, M.D.
Wilson J. Liao, M.D.
Leo Liebowitz
The Liebowitz Foundation
Clive M. Liu, M.D.
Brenda Lockhart
Virginia P. Louloudes
Patricia and Daniel Luck
Marvin and Kristina Lustiger
Thomas G. MacCracken
Mark and Jaclyn Marinovich
Orit Markowitz, M.D.
Mavena Derma Centers
Emanual Maverakis, M.D.
Penny E. McConnell
Thomas S. McCormick, Ph.D.
David G. McIntee
Robert and Valerie McLean
Brian McMaster
McMaster Family Foundation
Philip J. Mease, M.D.
M. J. Mecklenburg
Medimetriks Pharmaceuticals
Andrew Mitchell, M.D.
David and Sheila Mitchell
Scott Morgan
Warwick L. Morison, M.D.
Manuel R. Morman, M.D., Ph.D.
Mount Kisco Medical Group
Mount Sinai School of Medicine
Department of Dermatology
Mushatts
Ruth Mutch
National Biological Corporation
NeoStrata Company
Emil Neroda
New York Life Insurance
Newport Beachside Resort
Norfolk Southern Corp Good
Government Fund
Don and Rema Norton
Edith J. Oberman
Robert H. Oleksyn
Oregon Health & Science
University
Karen and Mark Oslund
Ed and Laura Owens
Pacific Marketing &
Publishing
Etahn Cohen & Amy Paller
Cohen
Roberta J. Palmer
Palo Alto Medical Foundation
Robert J. Pariser, M.D.
Erick Paulson
Linda and Michael Picciallo
Terilynn M. Pinkley
Pittsburgh Academy of
Dermatology
Ann Feder-Pomerantz
Robert B. Posnick, M.D.
Ken Preston
Paul H. Prigge
Qualcomm Incorporated
Abrar A. Qureshi, M.D.
Bruce and Mary Rabiner
Mike and Hulda Refermat
Valerie Richards, Ph.D.
Richards & Richards
Terrence J. Riley
Christopher Ritchlin, M.D.
Rite Care Pharmacy Specialty
& Compounding
Norman and Bettina Roberts
Foundation
Andrew D. Robertson, Ph.D. &
Sue M. Travis, Ph.D.
Rochdale Investment
Management
Claran Roche
Rogerio F. Rojas
Gerry Rosenberg and Cheryl
Wisenfeld Rosenberg
Randi B. Rosenblatt
Matthew Ross
George R. Russell, M.D.
Neil Sadick, M.D.
Alan and Joan Safir
Marc and Frances Samit
San Francisco Salt Co.
Sidney and Betsy Savelle
Richard and Wendy Schimel
Pamela B. Schultz
Jacci Seskin
Richard Sharpstein
Sue and Robert Shoenberg
Allen Shunk
Anne K. Silver
James S. Simpson
Howard L. Sofen, M.D.
Tracy F. Stein
Dorothy S. Stimpson
Stephen P. Stone, M.D.
Stout Industries Charitable
Foundation
Elizabeth and William Struve
Sunflower Dermatology &
Day Spa
Sussman Shank
Dina Tarro
Amy Forman Taub, M.D.
Craig F. Teller, M.D.
Therapeutics Clinical
Research
TKL Research
Total Life Care Pharmacy
James E. Turner, M.D., Ph.D.
Toni and James Turner
Stephen K. Tyring, M.D., Ph.D.
US Bank
Allison Vidimos, M.D.
Vrishali Wagle
Walgreens Specialty Pharmacy
Wallack Management Co.
Jacque Waller
Dawn and Steven Watts
Robert M. Weekley
Theodore & Renee Weiler
Foundation
Jeffrey M. Weinberg
Allison and Scott Weiss
Jonathan S. Weiss, M.D.
Roger K. West
Harry M. Wheeler
William and Barbara
Whittaker
Chris Williams
John S. Wilson
Windsor Dermatology
Johnnie Woodson, M.D.
World One Research
Edward Wright
George Wundsam
Joseph and Sylvia Yasgur
Elizabeth A. Young
Melodie Smith Young,
A.R.N.P.
Evelyn Zafran
Michael Zanolli, M.D.
Rolland Fritz Zeck
2012 ANNUAL REPORT • 15

BEQUESTS
The National Psoriasis Foundation honors the memory of those
who generously planned for estate gifts received in fiscal year 2012.
Photo courtesy of Mark Schlam
Seymour and Rebecca Lutto,
in memory of their son
Lawrence Lutto, $2 million,
the largest bequest in
Foundation history
(See pg. 9 for their story.)
Anonymous
Barbara D. Collins
Catherine M. Cunningham
Jesse & Millie Fusfeld
Family Trust
Hazel Grayson, in memory
of her daughter
Patricia J. Grayson
Mathilda A. Kamerman
Marian C. LaGodna
Thomas and Victoria
Maguda
Eugene G. Maurer
Harry Paulick
Marie R. Pitchford
Yuri Prizel
William Throckmorton
Putnam III
Tessie Wolk
LEGACY SOCIETY
Members have planned for future support by naming the National
Psoriasis Foundation as beneficiary in their will, trust, insurance
policy, retirement fund, charitable gift annuity or other estate plans.
CHARITABLE GIFT
ANNUITY
Benjamin and
Janice Isenberg
A special thanks to
longtime supporters
and Legacy Society
members who, in
FY2012, established
the Foundation’s
first Charitable Gift
Annuity.
Sandra Allison
Jack and Patricia Allweiss
Alexis M. Anderson
Anonymous (14)
Dot Aumann
Elsa Aybar
Corky L. Balzac
Robert and Cathleen Becker
George and Mary Bell
James P. Bennett, Ph.D.
Jeffrey B. Berman
Richard I. Besser
Frank M. Beveridge
Mary Kay Boylan
Robert L. Brooks
Richard Brotherston
LaVerne Beall Burhans
Mary B. Burrows
Laurie Anne Carlson
James Carolan
Howard and Lori Chang
Helene and Jerry Cotter
Enid L. Crook
Robert L. Crooks and
Sami J. Tucker
Paul Dodwell
Lucille Doree
Karen M. Durbak
Jackie Eber
Richard L. Elmendorf
Daniel and Rebecca
Farrington
Michael C. Finn, M.D.
Bruce and Susan Foat
Ruth I. Foerster
Carole and Marvin Frankel
Robert and Cynthia Galletly
Robert Ginsberg
Rich W. Good
Donald and Lesley Grilli
Bill and Mary Ann Grove
Louise K. Hawke
Mrs. Mary Beth Hedrick
Carol W. Henshaw
Jim Hergert
Lynn Hodges
Dr. Amy J. Holstein
Benjamin and Janice
Isenberg
Charles H. Jacobs
Betty Johnson
David W. Kapor
Diane and John Kazibut
Mara Kelly
Eric W. Kimble
William and Frances Klein
SaraLee and Barry Larner
Brian Larson
Patricia A. Laurie
Edward D. Lewis
Carl Wayne Littlejohn
Scott S. Lochridge
Charles Campbell Magee
Ellen Louise Magee
Mark and Jaclyn Marinovich
Craig and Irene McCall
Rebecca and John McCann
Sharon E. McCrae
Glennis McNeal
Kenneth A. Meersand
Linda Miller
Diane E. Moore
Marcy A. Morris
Mary L. Mullarkey
Chip Newton and Liz Smith
Robert J. Osterman
Ed and Laura Owens
Diane N. Paul
Harold and Harriet
Phillips
Eileen Prouty
Diane Robinson
Sherri A. Rosen
Marie D. Roser
Irvin J. Roth
Barbara and Paul Sanders
Pamela B. Schultz
Michael F. Score
Harold and Edna Seemann
Richard and Ellen Seiden
A. Marilyn Sime, Ph.D., R.N.
Timothy Jay Smith
Dr. Judith A. Snyder
Lisa Spiekermann
Steven Brad Stacey
Nell V. Steele
Jo Ann Steggerda
Brenda M. Tolley
Clivia Torres-Lacend
Cheryl K. Turay
Ruby B. Van Rooyen
Kenneth and
Mary J. Voertman
Jana R. and Stephen Wessels
Roger K. West
Margaret J. Whittle
Kevin Timothy Wilson
Gregory J. Winslow
Martha Wood
Robert P. Woodward
Charles and Marsha Woolley
Gloria Wren
Edward Wright
Evelyn Zafran
Susan K. Zeller
Gail M. Zimmerman
16 • NATIONAL PSORIASIS FOUNDATION

PRESIDENT’S COUNCIL
Medical professionals who demonstrate their commitment to
the patient community through their membership.
Elizabeth A. Abel, M.D.
William Abramovits, M.D.
Christine M. Adamick, M.D.
Donald J. Adler, D.O.
Andrew F. Alexis, M.D., M.P.H.
Laila Almeida, M.D.
Kenneth S. Alpern, M.D.
David J. Altman, M.D., Ph.D.
Lawrence L. Anderson, M.D.
Nancy J. Anderson, M.D.
Humberto C. Antunes
Peter J. Aronson, M.D.
Jerry Bagel, M.D.
Diane R. Baker, M.D.
Rodney S.W. Basler, M.D.
Eric W. Baum, M.D.
Vincent Peter Beltrani, Jr., M.D.
Paul R. Bergstresser, M.D.
Brian Berman, M.D., Ph.D.
J. Raymond Bernat, M.D.
Michael Bernhardt, M.D.
Neal Bhatia, M.D.
Joseph B. Bikowski, M.D.
Charles Birbara, M.D.
Andrew Blauvelt, M.D.
David Blum, M.D.
Erin E. Boh, M.D., Ph.D.
Mary Ruth Buchness, M.D.
Michael Bukhalo, M.D.
Daniel A. Buscaglia, D.O.
Jeffrey P. Callen, M.D.
Kristina Callis Duffin, M.D.
Charles Camisa, M.D.
Patrick Carney, M.D.
Carolina Mountain Dermatology
Daniel Carrasco, M.D.
Tamella B. Cassis, M.D.
Jennifer Clay Cather, M.D.
Robert L. Chappell, M.D.
May J. Chow, M.D.
David Clemons, M.D.
Missy M. Clifton, M.D.
Russell W. Cohen, M.D.
Steven R. Cohen, M.D., M.P.H.
Kevin D. Cooper, M.D.
Raymond L. Cornelison, Jr.,
M.D.
David J. Coynik, M.D.
Jeffrey Crowley, M.D.
Theodore Daly, M.D.
Kenneth Dawes, M.D.
Jim Del Rosso, D.O.
A. Damian Dhar, M.D.
N. Fred Eaglstein, D.O.
Joseph S. Eastern, M.D.
Craig A. Elmets, M.D.
Michelle Endicott, D.O.
John A. Erianne, M.D.
Colby C. Evans, M.D.
Lydia Evans, M.D.
John H. Exner, M.D.
Steven R. Feldman, M.D.,
Ph.D.
Neil A. Fenske, M.D.
A. Fernandez-Obregon, M.D.
David Fiorentino, M.D., Ph.D.
David P. Fivenson, M.D.
Mona Foad, M.D.
Michael Ford, M.D.
Joseph Francis Fowler, Jr., M.D.
Ellen H. Frankel, M.D.
Steven A. Franks, M.D.
Scott Fretzin, M.D.
Glenn H. Fuchs, M.D.
Loren S. Funt, M.D.
Bernard A. Gasch, M.D.
Joel M. Gelfand, M.D.
Brad P. Glick, D.O.
Bernard S. Goffe, M.D.
David J. Goldberg, M.D.
Michael T. Goldfarb, M.D.
Harry M. Goldin, M.D.
Roger S. Golomb, M.D.
Kenneth B. Gordon, M.D.
Alice Bendix Gottlieb, M.D.,
Ph.D.
Jennifer W. Gould, M.D.
Gloria F. Graham, M.D.
Richard D. Granstein, M.D.
Lawrence J. Green, M.D.
Harry L. Greenberg, M.D.
Joseph Greenberg, M.D.
Robert G. Greenberg, M.D.
Scott T. Guenthner, M.D.
Cynthia Guzzo, M.D.
Charles L. G. Halasz, M.D.
Tiffani K. Hamilton, M.D.
John G. Hancox, M.D.
Aubrey Chad Hartmann, M.D.
Sarah A. Haydel, M.D.
Stephen E. Helms, M.D.
David R. Hensley, M.D.
Warren R. Heymann, M.D.
Julie A. Hodge, M.D.
Deirdre Hooper, M.D.
Luciann L. Hruza, M.D.
Sylvia Hsu, M.D.
Charles Hudson, M.D.
Davide Iacobelli, M.D.
Francis W. Iacobellis, M.D.
Sarah C. Jackson, M.D.
J. Mark Jackson, M.D.
Robert L. Jackson, M.D.
Peter J. Jenkin, M.D.
Joseph L. Jorizzo, M.D.
Robert E. Kalb, M.D.
Susan E. Katz, M.D.
Leon Kircik, M.D.
John Y. M. Koo, M.D.
Neil Korman, M.D., Ph.D.
Craig A. Kraffert, M.D.
Cheryl Kramer
James M. Krell, M.D.
Indira Rao Krishnarao, M.D.
Gerald G. Krueger, M.D.
William V. Krug, M.D.
Sarah A. Kurts, PA-C
Michael A. Kurzman, M.D.
Richard Langley, M.D.
Stanton S. Lebouitz, M.D.
Mark G. Lebwohl, M.D.
Craig L. Leonardi, M.D.
Giulio A. Leone, M.D.
Jacob Levitt, M.D.
Ross S. Levy, M.D.
Gary D. Lichten, M.D.
Clive M. Liu, M.D.
Benjamin Lockshin, M.D.
Frederick A. Lupton III, M.D.
William Lynch, M.D.
Farah K. Malick, M.D.
Eugene Mandrea, M.D.
Linda Susan Marcus, M.D.
Barbara M. Mathes, M.D.
Robert T. Matheson, M.D.
Timothy D. Mattison, M.D.
Elizabeth I. McBurney, M.D.
Thomas S. McCormick, Ph.D.
Patrick S.J. McElgunn, M.D.
Philip J. Mease, M.D.
Alan M. Menter, M.D.
Lawrence S. Meyers, M.D.
Jami Lyn Miller, M.D.
Richard A. Miller, D.O.
Andrew J. Mitchell, M.D.
Craig Mohney, M.D.
Angela Yen Moore, M.D.
Warwick L. Morison, M.D.
Manuel R. Morman, M.D.,
Ph.D.
Mount Sinai School of
Medicine, Department of
Dermatology
George J. Murakawa, M.D.,
Ph.D.
John C. Murray, M.D.
Mark S. Nestor, M.D., Ph.D.
David S. Nieves, M.D.
Robert A. Norman, D.O.,
M.P.H.
Martin M. Okun, M.D.
Seth J. Orlow, M.D., Ph.D.
Patrick Ottuso, M.D.
Amy S. Paller, M.D.
Robert J. Pariser, M.D.
Jeffrey D. Pittis, M.D.
Justin Platzer, M.D.
Robert B. Posnick, M.D.
Steven A. Proper, M.D., M.P.H.
Ronald B. Prussick, M.D.
Abrar A. Qureshi, M.D.
John Karl Randall, M.D.,
R.Ph.
Oliver M. Reed, M.D.
Charles N. Reed, M.D.
Kathleen Remlinger, M.D.
Phoebe Rich, M.D.
Jennifer M. Ridge, M.D.
Darrell S. Rigel, M.D.
Christopher Ritchlin, M.D.
Douglas N. Robins, M.D.
Susan S. Roper, M.D.
Marti J. Rothe, M.D.
Beata L. Rydzik, M.D.
Neil Sadick, M.D.
Hans M. Sander, M.D.
Michael A. Scannon, M.D.
Robert F. Schwarze, D.O.
David C. Semler, M.D.
Kara Shah, M.D.
Kerry Shafran, M.D.
Patrick Shannon, M.D.
Mary E. Shepherd, M.D., Ph.D.
Jerome L. Shupack, M.D.
Michael T. Siegel, M.D.
David N. Silvers, M.D.
Robert A. Snyder, M.D.
Howard L. Sofen, M.D.
Mark Steele, NeoStrata
Company
Linda Stein Gold, M.D.
Seth R. Stevens, M.D.
Lawrence M. Stokar, M.D.
Stephen P. Stone, M.D.
Timothy Jon Storer, M.D.
Bruce E. Strober, M.D., Ph.D.
Emil A. Tanghetti, M.D.
Artthapol Tanphaichitr, M.D.
Amy Forman Taub, M.D.
Craig F. Teller, M.D.
Ira H. Thorla, Jr., M.D.
Cynthia Tie, M.D.
Helen Mary Torok, M.D.
Eric S. Treiber, M.D.
Ruth K. Treiber, M.D.
James E. Turner, M.D., Ph.D.
Stephen K. Tyring, M.D.,
Ph.D.
Eugene J. Van Scott, M.D.
Abby S. Van Voorhees, M.D.
Panos Vasiloudes, M.D., Ph.D.
Allison Vidimos, M.D.
K. Dawn Vincent, M.D.
Paul Wallace, M.D.
Robert R. Walther, M.D.
Guy Webster, M.D., Ph.D.
Jeffrey M. Weinberg, M.D.
Gerald D. Weinstein, M.D.
Jonathan S. Weiss, M.D.
Stefan Weiss, M.D.
Schield M. Wikas, D.O.
Johnnie Woodson, M.D.
Paul S. Yamauchi, M.D., Ph.D.
Joseph J. Zaladonis, Jr., M.D.
Michael Zanolli, M.D.
2012 ANNUAL REPORT • 17

TOP WALK TEAMS 2011-2012
JULY 1, 2011–JUNE 30, 2012
Thank you to our
Walk to Cure Psoriasis
Corporate Sponsors:
PRESENTING SPONSOR
Laub Weiss Team
Carol Laub
Henschels Victors
Jamie Henschel
Team 11,12,13 Challenge
Kathryn Markham
Pop’s Dream
Neal Henschel
Steph’s Striders
Stephanie Gearhart
Rick’s Team
Rick Seiden
Bender’s Helpers
Dean Bender
Team Alyssa
Alyssa Krafsur
Team Janssen
Arlene Bitmansour
PSam Psays Pso What
Sam Lichten
Refermat Smack Down
Allison Refermat
Team JBI
Priscilla Tavener
Savanna’s Priority 4 Psoriasis
Savanna Swanson
Bender family
Janice Bender
TEAM SAM
Sam Weinbaum
Beth’s Buddies
Beth/David Geduld
Galderma Laboratories
David Scriven
University of Utah Dermatology
Kristina Duffin
Team Virtual
Chip Newton
Team Cardine
Corey Cardine
Pso Jeffrey
Jeffrey Henschel
NATIONAL SPONSORS
American Airlines Flight Crew
Gabba-goo Crew
Itchin’ to Walk
Walkers & Talkers
Team Hannah Banana
UCSF Psoriasis Center
Team Cohen
UPenn Dermatology
Team Amgen LA
Ron Grau
Team K
PSOul PSOlution
Finks
Cross Country Aches and Pflakes
Nicky’s Patch
Soles for Psoriasis
Team Melanie
Bellaire Dermatology Associates
PAMF PASIs
Abbott Team
Team Baker
Walgreens Team SLC
Team Jojo
Hunnibell-Moroney
Team DAVEN
Raising Money for a Cure!
Walk with Erin
Team Fayetteville
phillywalkfriends
Team Menter
Joint Relief
UCLA Derm Team
Team McKenna
Team Wisse
TOP LOCAL SPONSORS
Abbott Immunology
Chicago
Neutrogena
Los Angeles
Aventura Mall
South Florida
Altman Dermatology Associates
Chicago
Drinker Biddle & Reath
Washington, D.C.
Infinite Healthcare Partners LLC
South Florida
OTIS
San Diego
MISSION:
To find a cure for psoriasis and psoriatic arthritis and to eliminate
their devastating effects through research, advocacy and education.
6600 SW 92nd Ave., Suite 300
Portland, OR 97223-7195
Telephone: 503.244.7404 | 800.723.9166 | Fax: 503.245.0626
Website: www.psoriasis.org | Email: getinfo@psoriasis.org